ARQTArcutis Biotherapeutics, Inc.

Nasdaq arcutis.com


$ 9.59 $ 0.72 (8.11 %)    

Tuesday, 25-Jun-2024 15:59:57 EDT
QQQ $ 479.35 $ 5.42 (1.14 %)
DIA $ 391.06 $ -2.96 (-0.75 %)
SPY $ 544.78 $ 2.09 (0.39 %)
TLT $ 94.49 $ 0.16 (0.17 %)
GLD $ 214.55 $ -1.07 (-0.5 %)
$ 9.6
$ 8.84
$ 9.35 x 5,200
$ 9.59 x 400
$ 8.56 - $ 9.63
$ 1.76 - $ 13.17
2,418,673
na
1.07B
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-03-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 02-22-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-12-2020 03-31-2020 10-Q
18 03-19-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 arcutis-presents-new-long-term-data-of-roflumilast-cream-015-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-adults-and-children-down-to-age-6-at-the-revolutionizing-alopecia-areata-vitiligo-and-eczema-conference

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through ...

 arcutis-reports-multiple-abstracts-including-oral-presentation-at-the-revolutionizing-alopecia-areata-vitiligo-and-eczema-conference-from-june-8-10-2024

New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be...

 needham-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-18

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

Core News & Articles
Market-Moving News for May 15th
05/15/2024 12:33:09

EDBL: 87% | Edible Garden shares are trading higher. The company reported Q1 financial results. MNDY: 22% | Monday.com shares ...

 mizuho-maintains-buy-on-arcutis-biotherapeutics-raises-price-target-to-18

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $17 to $18.

 arcutis-biotherapeutics-stock-climbs-after-blockbuster-q1-results

Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.

 arcutis-biotherapeutics-q1-2024-adj-eps-032-beats-073-estimate-sales-4957m-beat-1468m-estimate

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate ...

 the-journal-of-clinical-and-aesthetic-dermatology-published-arcutis-biotherapeutics-outcomes-of-a-comprehensive-evaluation-by-an-expert-dermatologist-panel-assessing-the-formulation-ingredients-of-zoryve-topical-foam-03

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin...

 needham-reiterates-buy-on-arcutis-biotherapeutics-maintains-16-price-target

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.

 eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

 arcutis-announces-acceptance-of-late-breaking-abstract-in-atopic-dermatitis-among-five-new-topical-roflumilast-data-being-presented-at-the-american-academy-of-dermatology-annual-meeting

Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages ...